We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 46

Corporate venture funding for funding surges

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 7 2014

Silicon Valley Bank (SVB) has issued a report that explores health-care and biotech investments and exits based on 2013 data and concludes, "Large

Veracyte increases IPO target to $81 million

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 31 2013

South San Francisco-based Veracyte, Inc., which earlier this year completed a $28-million Series C financing round to expand and roll out its thyroid

Biotech IPO market, booming or bubbling?

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • October 17 2013

Speakers at a recent Biotechnology Industry Organization (BIO) Investor Forum in San Francisco reportedly claimed that this year's successes for

Pharma and biotech stocks rise, M&A and IPO values strong, licensing deals

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Market analysts commenting on the dramatic rise in the Nasdaq Biotech Index (up 27) and the Dow Jones US Pharma Index (up 21) in the first half of

Molecular diagnostics company nets $27.7 million from common stock offering

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • September 26 2013

Illinois-based Nanosphere, Inc. has reportedly closed a public offering of more than 17 million shares of common stock at $1.75 per share, including

Royalty financing gains favor for VC biotech funding

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 29 2013

According to a former venture capitalist (VC), a recent deal involving a royalty in exchange for a cash infusion to develop and commercialize a

Biotech IPO boom continues

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 1 2013

According to Xconomy's National Biotech Editor Luke Timmerman, the 24 biotech initial public offerings (IPOs) in 2013 are double those normally seen

Biotech raises $30 million to develop rare muscle disease treatments

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • August 1 2013

San Francisco-based Audentes Therapeutics Inc. has closed a $30-million Series A financing round led by OrbiMed Advisors and including 5AM Ventures

EU firms to step up investment in Chinese cosmetics companies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • June 13 2013

European Union (EU) cosmetics companies reportedly intend to expand investment in China despite some concerns about rising labor costs, sluggish

U.S. biotech sector shows IPO gains in 2013

  • Shook Hardy & Bacon LLP
  • -
  • USA
  • -
  • June 6 2013

According to Reuters, 14 biotech companies have gone public so far in 2013, marking a possible turnaround for the sector with a rising stock market